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Development and application of an enzyme-linked immunosorbent
assay for detection of bovine viral diarrhea antibody based on Erns
glycoprotein expressed in a baculovirus system
E. Grego, F. Uslenghi, M. Strasser, C. Luzzago, M. Frigerio, S. Peletto, S. Rosati1
Abstract. The BVDV envelope glycoprotein Erns/gp48 and the C terminal 79 amino acids of the capsid
protein coding region were expressed in a baculovirus system and antigenically characterized. Western blot
assay was used to detect recombinant Erns (r-Erns) in infected insect cells using specific monoclonal antibodies.
The r-Erns was then used in an indirect ELISA to detect BVDV specific antibodies in a panel of 540 well-
characterized sera. Results of the r-Erns ELISA were compared to those obtained with a commercially available
competitive ELISA targeting anti-NS2/3 antibodies. A good correlation was observed between the 2 ELISA
(kappa 5 0.916, 95% C.I.: 0.876, 0.956). Using the commercial NS2/3 ELISA as the reference test, the relative
sensitivity of r-Erns ELISA was 97.5% (95% C.I.: 94.3%, 99.1%) and the relative specificity was 93.9% (95%
C.I.: 89.4%, 96.9%), while relative specificity was 100% (95% C.I.: 97%, 100%) using true negative sera
(derived from a negative herd). All but 1 antigen positive animals (n 5 36) tested negative in the r-Erns ELISA;
among them all 22 confirmed PI animals were negative by r-Erns ELISA. The ability of r-Erns ELISA to identify
cattle immunized with inactivated vaccine was also demonstrated in a small group of cattle, compared to an
NS2/3 antibody ELISA. Results suggest that r-Erns ELISA represents an alternative test for antibody
generated by natural infection or BVDV vaccination.
Key words: Baculovirus; bovine viral diarrhea virus; ELISA; Erns glycoprotein.
Introduction
Bovine viral diarrhea virus (BVDV) is classified in
the pestivirus genus of the Flaviviridae family.
Members of this genus include classical swine fever
virus (CSFV) and border disease virus (BDV).11
BVDV is responsible for reproductive, enteric, and
respiratory syndromes and causes considerable eco-
nomic loss to cattle farms throughout the world.8,26,27
The infection is sustained in the population by
persistently infected (PI) animals14,18 that are immu-
notolerant to the persisting virus strain due to
initiation of infection early in their intrauterine
development.1,8 This unique phenomenon is the
primary mechanism whereby BVDV is maintained
in cattle populations, providing for direct and indirect
transmission.6 Such PI animals shed the virus through
secretions and excretions and may, over months or
years, develop an invariably fatal disease known as
mucosal disease as a result of mutation of persisting
virus or superinfection with an antigenically related
heterologous strain.7 Therefore, control and eradica-
tion programs must focus on prevention of persistent
infection and identification and removal of PI
animals.5 Although PI animals constitute a major
source of virus spread, transiently infected animals
may be the primary source of virus introduction into
naive herds. In most cases, the transient infection
produces reproductive and respiratory disease, which
results in major economic losses to the cattle industry.
However, occasionally severe disease characterized by
hemorrhages is observed.13,24,27,30,31,34
In low cattle population density areas, eradication
of BVDV without vaccination has proven to be
successful, whereas in high population density or high
seroprevalence areas, control measures are usually
carried out by systematic vaccination of cattle.17 It
should be borne in mind that, due to antigenic
variability, vaccination alone cannot guarantee full
protection against all viral strains, and there is need to
improve the efficacy and safety of BVDV vac-
cines.16,35
A number of diagnostic tests have been developed
to detect antibodies or viral antigens or nucleic acid at
the herd and individual level. Infected herds are
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usually identified by spot test (testing animals of
a certain age or groups of animals housed in different
units), bulk milk test for antibodies, or nucleic acid
amplification.17,25,28 Once the infected herds are
identified, individual tests are used to remove PI
animals. In regard to the presence of circulating
antibodies or virus, 3 main categories of animals can
be differentiated: 1) seropositive and virus negative
animals due to previous transient infections or
vaccination, 2) immunologically naive animals, and
3) virus-positive animals as a result of persistent or
transient infection.6 PI animals usually remain
negative for antibody against the conserved epitopes
of structural and nonstructural proteins; however,
a superinfection with an antigenically different BVDV
strain may induce an immune response against
variable epitopes, mainly located in the E2 envelope
glycoprotein.3,16 Serological tests are available to
detect antibodies against both variable proteins
(serum neutralization test (SNT)) and conserved
proteins (competitive NS2/3 ELISA). The latter test,
based on a monoclonal antibody directed against
a highly conserved epitope of NS2/3, has proven to be
highly sensitive in detecting antibodies in transiently
infected animals or animals vaccinated with a live
attenuated vaccine.2 However, due to insufficient
amount of this nonstructural protein in most killed
vaccines, this test may fail to detect antibodies in
animals that have been immunized with inactivated
vaccine.
Among viral structural proteins the Erns glycopro-
tein has been shown to be a useful marker for
identification of PI animals, since it is genetically and
antigenically conserved among different isolates.22
Indeed, several studies have indicated that some of
the immunologically relevant Erns epitopes are con-
served among different BVDV isolates,4,12,23,36 and
few differences are found in Erns amino acid compo-
sition among different pestiviruses.19 Little is known
about its potential as a serological marker of BVDV
infection. Recombinant Erns or its subunit, expressed
in prokaryotic and baculovirus systems, has been
used as an antigen to specifically detect anti Erns
antibodies in a limited number of samples with
promising results,23,29,37 but the application on a lar-
ge number of well-characterized samples is still
necessary for more complete validation. In this study,
the Erns and the C terminal 79 amino acids of the
capsid protein coding region were expressed in
a baculovirus system. The resulting antigen was used
to develop an indirect ELISA that was validated
using a panel of sera from transiently infected
animals, animals immunized with inactivated
vaccine, PI animals, and immunologically naive
animals.
Materials and methods
Virus and cells
The Oregon C24 strain of BVDV was cultured in Madin
Darby bovine kidney (MDBK) cells maintained in Earle
minimal essential medium supplemented with 10% pesti-
virus-free fetal calf seruma and antibiotic-antimycotic
solution (penicillin 100 UI/ml, streptomycin 100 mg/ml,
amphotericin B 0.25 mg/ml). Linearized Autographa cali-
fornica multiple nuclear polyhedrosis virus (AcMNPV)
DNA was used to generate recombinant baculovirus.
Spodoptera frugiperda (Sf9 or Sf21) cell linesa were grown
in TNM-FH Insect Medium (Modified Grace Medium)k
with 10% fetal calf serum, antibiotic-antimycotic solution,
and were used for transfection and plaque purification and
to generate high-titer recombinant viral stocks. The SF21
cell line was adapted to Sf900II protein-free medium
according to a direct method protocola and used for time-
course expression and large-scale expression of recombi-
nant protein.
Construction of recombinant baculoviruses
Total RNA was extracted from infected MDBK cell
cultures using RNeasy total RNA kitb and reverse
transcribed in a 20-ml reaction containing 20 U AMV
reverse transcriptase,c 0.1 A260 U random hexamers, 1 mM
dNTPs, and 2–3 mg total RNA, according to the manu-
facturer’s protocol. The primers used to amplify the Erns
gene and part of the capsid protein coding region were:
forward primer 59 TTGGATCCATGAAAATAGTGCC-
CAAAGAGT 39, reverse primer 59 TTGAATTCAGCCG-
CATATGCTCCAAACCACGT 39. Primers contained the
BamH1 and EcoR1 recognition site (underlined), respec-
tively, at the 59 end to facilitate cloning. Five ml of cDNA
was added to 45 ml of PCR mix containing 10 mM Tris-
HCl, 50 mM KCl, 2 mM MgCl2, 0.2 mM dNTPs, 10 pM
of each primers, and 2 U of AmpliTaq Gold.d Thermo-
cycling parameters consisted of an initial denaturation step
(94uC, 10 min) followed by 40 cycles of denaturation (94uC,
1 min), annealing (50uC, 1 min), and extension (72uC,
2 min). The purified PCR product was digested with
BamHI and EcoRI restriction enzymes and ligated into
the baculovirus shuttle vectors pBlueBacHis2A and pMel-
BacA.a The former allows purification of protein of interest
using metal chelate affinity chromatography, while the
latter directs the expression of the recombinant protein
through the secretory pathway to the extracellular medium.
Escherichia coli TOP10a was transformed with ligation
mixtures and used to generate midipreparation (100-mg
scale) of each recombinant plasmid. Sequence analysis of
the insert was carried out with fluorescent dye terminators
on an ABI PRISM 310 Genetic Analyzerd according to the
manufacturer’s protocol. Purified plasmids were used to
cotransfect Sf9 insect cells with linearized AcMNPV DNA
using liposome reagent cellfectin.a After 3 days of in-
cubation at 27uC, the supernatant was harvested and
recombinant virus was purified by plaque assay. Positive
plaques were selected and amplified in a 24-well microplate.
After 7–10 days, a PCR control was carried out using
vector primers designed to bind the flanking region of the
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insert, allowing the detection of recombinant baculovirus
(expected length 1,259 bp) as well as any contaminating
wild-type baculovirus (expected length 839 bp). Recombi-
nant baculovirus was used to infect Sf21 insect cells to
generate high-titer viral stock, which was titrated by plaque
assay. Recombinant baculoviruses obtained using pBlue-
Bac and pMelBac vectors were identified as Bac/Erns and
Mel/Erns, respectively. All technical methods were carried
out according to the manufacturer’s instruction manual.a
Location and peak of expression were estimated using
a sandwich ELISA,e which was developed for identification
of PI animals through specific detection of native Erns in
serum samples.
Production and characterization of recombinant antigen
Sf21 cells were infected with the recombinant baculovirus
at a multiplicity of infection (MOI) of 10 PFU/cell. Cells
were harvested 72 hr postinfection, washed with phos-
phate-buffered saline (PBS), and used as whole antigen for
Western blot analysis, using commercially available anti-
6xHisf and anti-Erns e monoclonal antibodies (MAbs).
Western blot was carried out following conventional
methods.9 For antigen preparation, Sf21 cells were infected
with the recombinant baculovirus at a multiplicity of
infection (MOI) of 10 PFU/cell. At 72 hr postinfection, cell
monolayers were washed with PBS and lysed with 150 mM
NaCl, 50 mM Tris HCl pH 8.0, and 1% Igepal. The
mixture was first incubated at 280uC for 1 hr and, after
thawing, clarified at low-speed centrifugation. Supernatant
was further centrifuged at 8000 3 g for 20 min at 4uC and
stored in aliquots at 280uC. The protein concentration of
the total cell lysate was estimated by DC Protein Assay.g
Serum samples
A panel of 540 bovine sera, collected mainly from 6
different Italian herds, was used in this study. Among these,
100 serum samples were collected from true negative
herds.24,26 The negative status of these herds was de-
termined using SNT and NS2/3 competitive ELISA, by
testing either all animals or a sample size that allowed the
detection of prevalence of infection $10% (95% confidence
level).10 Thirty-six sera were from antigen-positive subjects,
identified from different herds in Northern Italy by antigen
ELISA or RT-PCR, and 22 of those were proven to be PI
animals by positive retesting after 2 weeks; 384 sera were
from infected farms where at least 1 PI animal had been
detected. Among the latter group seropositives and
seronegatives were previously classified using a commer-
cially available competitive ELISA detecting anti-NS2/3
antibodies.i Finally, 20 sera were collected from 10 animals,
aged 6–8 mo, immunized with 2 doses of inactivated
vaccineh at a 1-mo interval. Sera were collected before
vaccination and 1 mo after the second administration.
Recombinant Erns protein-based antibody ELISA
For r-Erns antibody ELISA, 2 different coating proce-
dures were tested. The first procedure consisted of coating
microplates overnight at 4uC with 1 mg/well (odd columns)
of infected cell lysate diluted in carbonate/bicarbonate
buffer, or the same amount of negative antigen (even
columns), prepared from mock infected Sf21 cells. After 3
washes with ELISA wash (0.125 mM NaCl, 0.05% Triton
3100) microplates were used for ELISA. In the second
procedure, microplates were coated overnight at 4uC with
1 mg/well of an anti-Erns noncompeting MabJ diluted in
carbonate/bicarbonate buffer. The next day, plates were
washed twice and blocked with casein buffer (2.5% casein,
0.375 mM NaCl pH 7) at 37uC for 1 hr. Following four
washing steps, the insect cell lysate containing expressed
Erns was diluted to 2 mg/well in PBS and added to MAb-
coated plates. After 1 hr incubation at 37uC, plates were
washed 3 times and used for ELISA. In a preliminary phase
both coating methods were used to analyze a subset of
serum samples, then the second coating method was
chosen. Duplicate antigen-coated wells were incubated for
1 hr at 37uC with test serum diluted 1/40 in PBS containing
1.25% casein. Plates were washed 3 times and incubated
with 5 ng/well of peroxidase-conjugated anti-bovine IgG
(diluted in the same buffer as before) for 1 hr at 37uC. After
the final washing step, reaction was developed with 2,29-
azino-bis(3-ethylbenziazoline-6-sulfonic acid) (ABTS) for
20 min and optical density (OD) measured at 405 nm. The
mean OD from duplicate wells of each sample was
expressed as a percentage of the OD of the positive control.
The latter was a pool of 4 serum samples positive in the
NS2/3 ELISA.
Statistical analysis
Receiver operating characteristic (ROC) analysis of the
ELISA results was performed using the R software.20 An
optimum cutoff, corresponding with the highest accuracy
(i.e., minimal false-negative and false-positive results), was
determined. Serum samples yielding $25% of the OD of the
positive control (included in each plate) were considered to be
positive. Concordance between r-Erns ELISA and the
commercial NS2/3 competitive ELISA was evaluated using
the Kappa statistic,15 while descriptive statistics and distri-
bution of reactivity of each group of samples were obtained
using the R software.20 Relative sensitivity and specificity
were calculated using binomial test function in R.20
Results
Results demonstrated that Bac/Erns and Mel/Erns
infected cells were both highly reactive by sandwich
ELISA, with an expression peak at 72 hr p.i. (post
infection) and at 96 hr p.i., respectively (Fig. 1).
However, in Bac/Erns infected cells, the signals were
mainly cell-associated, whereas in Mel/Erns infected
cells, r-Erns was found secreted in the medium.
Western blot analysis of total cell lysate, using anti-
Erns and anti-6xHis MAbs, revealed a major protein
band with a molecular mass slightly lower than the
expected size (Fig. 2). Preliminary attempts to obtain
r-Erns in purified form from Bac/Erns infected cells
using affinity chromatography under native or de-
naturing conditions were unsuccessful. Recombinant
Erns, obtained in secreted form into the SF900II
BVDV Erns Antibody ELISA 23
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medium using Mel/Erns infected cells, was found to
rapidly degrade after storage at 280uC. Therefore,
antigenic characterization of r-Erns as a serological
marker of BVDV infection was carried out using
a crude Bac/Erns infected cell lysate. When crude cell
lysate was used for direct coating of microplates,
a number of false positive reactions were recorded in
spite of correction for background staining by
subtracting the OD of negative antigen. Using
a noncompeting MAb as a capture antibody, no false
positives were detected using true negative samples;
therefore, the characterization of the entire serum
panel was carried out using that method. Distribution
of ELISA ODs for each group of serum samples is
shown in Fig. 3. The specificity of Erns ELISA using
100 true negative sera was 100% (95% C.I.: 97%,
100%). Among 36 antigen positive animals, all were
negative by NS2/3 ELISA; samples from all 22 PI
animals and 13 out of 14 antigen positive samples
(not proven to be PI animals) were also negative by
Erns ELISA. The relative specificity and sensitivity of
Erns ELISA, using 182 negative sera and 202 positive
sera previously classified by NS2/3 ELISA, were
respectively 93.9% (95% C.I.: 89.4%, 96.9%) and
97.5% (95% C.I.: 94.3%, 99.1%). Agreement between
Erns ELISA and NS2/3 competitive ELISA, evaluated
on 3 infected farms, was excellent (kappa 5 0.916,
95% C.I.: 0.876, 0.956).
When the ability of Erns ELISA to detect animals
immunized with inactivated vaccine was evaluated
1 month after the booster vaccination, all samples
scored negative to NS2/3 ELISA, while 9 out of 10
showed a clear seroconversion against r-Erns (Fig. 4).
Discussion
In this study, the diagnostic value of r-Erns
expressed in baculovirus as a serological marker of
BVDV infection was evaluated. The rationale for this
approach was based on 2 properties of the Erns. First,
the gene encoding this glycoprotein is relatively
conserved in the different viral strains of both
genotypes.19,23,32 Second, Erns is able to induce a rapid
immune response during viral infection in immuno-
competent animals.23 The baculovirus expression
system is known to generate a high amount of viral
glycoprotein preserving major posttranslational mod-
ifications and antigenicity.21 Immunotolerant and
persistently infected animals should remain antibody
negative against conserved epitopes and should be
nonreactive against this glycoprotein. Several studies
demonstrate that PI animals are able to respond to
BVDV immunogens different from the specific BVDV
inducing immunotolerance.3,16 However, in these
studies the presence of antibodies in PI animals was
exclusively detected using the SNT when a PI subject
is superinfected with an antigenically different BVDV
strain. Although Erns may induce neutralizing anti-
bodies, E2 is the most important structural protein
involved in the production of such antibodies. This
glycoprotein, unlike Erns, is highly variable among
genotypes and, to some extent, within subtypes.16
Changes in the E2 glycoprotein are the primary sites
of variation in neutralizing epitopes.6
In the system used in this study, the r-Erns was
efficiently expressed and the infection of a 100-mm
monolayer plate (about 12 3 106 cells) produced
enough antigen to test 4,400 sera using the described
conditions. Preliminary antigenic characterization
using 2 anti-Erns MAbs showed that at least 2 epitopes
were preserved in the recombinant protein. Native
Erns lacks a typical membrane anchor and is released
in a soluble form in viremic subjects.32,33 This
property was also observed in the r-Erns and further
enhanced using Mel/Erns infected cells in which the
Figure 1. Time course expression and localization of r-Erns in Bac/ Erns and Mel/ Erns infected insect cells, revealed by
sandwich ELISA.e
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upstream signal sequence for honeybee mellitin is
used to direct secretion of the recombinant protein.
The use of crude insect cell lysate has been
suggested as a practical advantage for the production
of diagnostically useful antigen for BVDV diagnosis
due to the low level of nonspecific reactions against
insect proteins.29 However, the results from this study
indicate that purification of the recombinant antigen
from crude insect cell lysate might be required for
optimal specificity in an indirect ELISA system.
However, the need to purify r-Erns was obviated by
utilizing a commercially available MAb to capture
BVDV-specific antigen from the crude cell lysate. R-
Erns ELISA showed 100% specificity when used to test
100 negative samples recovered from farms where the
negative BVDV status had been clearly determined.
All samples from 22 PI animals, supposed to be
antibody negative against conserved epitopes, were
also negative in the Erns ELISA. A lower value of
specificity was obtained in comparison with NS2/3
ELISA (93.9%). While attenuated vaccine may induce
an antibody response against structural and non-
structural viral protein similar to transient infection,
inactivated vaccine may induce response only against
structural proteins. This may reflect the ability of Erns
ELISA to identify animals immunized with inacti-
vated vaccine, a common control measure in Italian
farms, and confirms a previous study carried out on
recombinant BVDV antigen expressed in prokaryotic
and baculovirus systems.23 To further confirm this
hypothesis, a group of animals was vaccinated with 2
doses of inactivated vaccine, and a clear seroconver-
sion was recorded by r-Erns ELISA but not by NS2/3
ELISA. The inactivated vaccine used for immuniza-
tion in this study was tested by a sandwich ELISA to
detect the presence of native Erns and a very high
signal was detected (data not shown), suggesting that
Erns was highly expressed and preserved during
vaccine preparation. The low immunogenic properties
of NS2/3 in killed vaccines may be related to trace
amounts of this nonstructural protein in vaccine
preparation due to a lower expression, compared to
structural proteins, and/or removal by final filtration
in some vaccine preparations. The fact that Erns lacks
an anchor site may lead one to assume an NS2/3-like
behavior. It will therefore be necessary to evaluate
different killed vaccine preparations to confirm the
ability of the test proposed in this study to identify
immunized animals. When the sensitivity of r-Erns
ELISA was evaluated using sera from infected herds
and previously classified by NS2/3 ELISA, excellent
agreement was observed. Finally, all but 1 virus-
positive animal did not react against r-Erns ELISA.
The lone reactor was a 2-year-old cow belonging to
an infected herd which was slaughtered before it
could be retested to ascertain PI status. If this animal
was transiently infected, it is possible that it might
have been tested during a very narrow window in
Figure 3. r-Erns ELISA. boxplot of mean ODs (expressed as
percentage of reactivity of the positive reference serum) of the
serum panel used in the study; Ag+: 36 virus positive animals (by
antigen or nucleic acid detection) of which 22 were PI animals;
NS2/3Ab2 and NS2/3Ab+: 384 sera from infected farms classified
by NS2/3 ELISA; TN: 100 truly negative sera.
Figure 2. Western blot analysis of Bac/ Erns infected insect
cells at 72 hr p.i. M: prestained MW markers; lane 1: anti-6xHis
MAb; lane 2: anti-Erns MAb; lane 3: 6xHis control recom-
binant protein.
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which viral antigen (captured by the noncompeting
MAb) and anti-Erns antibodies were present at the
same time. However, since neutralization test and
NS2/3 antibody ELISA were both negative, a false-
positive reaction with the r-Erns ELISA likely oc-
curred in a true PI animal or in an animal during the
early stages of a transient infection. With the
exception of this possible false positive, the r-Erns
ELISA proved to be a highly reliable antibody test.
In conclusion, the Erns protein, expressed in
a baculovirus-based eukaryotic system, preserves the
antigenicity of the native protein. The ELISA de-
scribed herein based on the baculovirus r-Erns protein
may be a useful alternative serological test for
detecting antibodies from transient infections or
vaccination with BVDV.
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